The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Alzheimer's disease drug development pipeline: 2018
Open accessAbstract
Introduction: Treatments for Alzheimer's disease (AD) are needed due to the growing number of individuals with preclinical, prodromal, and dementia forms of AD. Drug development for AD therapies can be examined by inspecting the drug development pipeline as represented on clinicaltrials.gov . Methods: Clinicaltrials.gov was assessed as of January 30, 2018 to determine AD therapies represented in phase I, phase II, and phase III. Results: There are 112 agents in the current AD treatment pipeline. There are 26 agents in 35 trials in phase III, 63 agents in 75 trials in phase II, and 23 agents in 25 trials in phase I. A review of the mechanisms of actions of the agents in the pipeline shows that 63% are disease‐modifying therapies, 22% are symptomatic cognitive enhancers, and 12% are symptomatic agents addressing neuropsychiatric and behavioral changes. Trials in phase III are larger and longer than phase II or phase I trials, particularly those involving disease‐modifying agents. Comparison with the 2017 pipeline shows that there are four new agents in phase III, 14 in phase II, and eight in phase I. Inspection of the use of biomarkers as revealed on clinicaltrials.gov shows that amyloid biomarkers are used as entry criterion in 14 phase III disease‐modifying agent trials and 17 disease‐modifying agent trials in phase II. Twenty‐one trials of disease‐modifying agents in phase II did not require biomarker confirmation for AD at trial entry. Discussion: The AD drug development pipeline is slightly larger in 2018 than in 2017. Trials increasingly include preclinical and prodromal populations. There is an increase in nonamyloid mechanisms of action for drugs in earlier phases of drug development. Biomarkers are increasingly used in AD drug development but are not used uniformly for AD diagnosis confirmation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, the literature review reveals that only a single cholinesterase inhibitor is in Phase II and Phase III clinical trials, for AD management [147,148].”
From Acetylcholinesterase Inhibitory Potential of Various Sesquiterpene Analogues for Alzheimer’s Disease Therapy (2021) · cites this paper as [148]
In the citing paper
“A number of additional pathogenic mechanisms have been described, possibly overlapping with Aβ plaques and NFT formation or induced by them, including inflammation, oxidative damage, iron deregulation, and cholesterol metabolism blood-brain barrier (BBB) dysfunction or α-synuclein toxicity.9-13”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152
Forecasting the global burden of Alzheimer's disease
Brookmeyer, R., Johnson, E., Ziegler‐Graham, K., & Arrighi, H. M. (2007) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2007.04.381 · Cited by 3,370
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70090-0 · Cited by 3,321
Self-citationScheltens, P., Blennow, K., Breteler, M. M. B., de Strooper, B., Frisoni, G. B., Salloway, S., & Van der Flier, W. M. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01124-1 · Cited by 3,125
Masters, C. L., Bateman, R., Blennow, K., Rowe, C. C., Sperling, R. A., & Cummings, J. L. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.56 · Cited by 1,853
Self-citationAlzheimer’s disease drug-development pipeline: Few candidates, frequent failures
Cummings, J. L., Morstorf, T., & Zhong, K. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt269 · Cited by 1,744
Self-citationEpidemiology of Alzheimer disease
Reitz, C., Brayne, C., & Mayeux, R. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.2 · Cited by 1,675
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668
Clinical Trial Registration: A Statement from the International Committee of Medical Journal Editors
De Angelis, C., Drazen, J. M., Frizelle, F. A., Haug, C., Hoey, J., Horton, R., Kotzin, S., Laine, C., Marusic, A., Overbeke, A. J. P. M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejme048225 · Cited by 1,241
Flagged first, then by citations
Research works printed but not linked: 1
- Lombardo I., 2017, Results from the phase 3 MINDSET STUDY: a global, double‐blind, placebo‐controlled study of intepirdine in mild‐to‐moderate Alzheimer's disease
Cited by
Sorted by citations
Items 601–700 of 701
Regenerative nanomedicine applications for neurodegenerative diseases of central nervous system
Alkhalifa, H., Alshebber, E., & Taurin, S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-820466-5.00012-0 · Cited by 2
Pharmakologische Therapie der Alzheimer-Demenz: Aktueller Stand und Perspektiven
Müller, P., Fendt, M., & Müller, N. (2019) · Der Internist · Cited by 2
Wimo, A. B. (2020) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2021.1848551 · Cited by 2
Alzheimer’s Disease: Cellular and Pharmacological Aspects
Aranda-Abreu, G. E., Rojas-Durán, F., Hernández‐Aguilar, M. E., Herrera‐Covarrubias, D., Chi-Castañeda, D., Toledo‐Cárdenas, M. R., & Suárez-Medellín, J. M. (2024) · Geriatrics · doi:10.3390/geriatrics9040086 · Cited by 2
Jeong, Y. H., Jung, Y., Li, W., Yang, H. J., Oh, Y.-C., & Bae, J. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1638068 · Cited by 1
Pacheco-Sánchez, B., Verheul-Campos, J., Vargas, A., Tovar, R., Rodríguez-Pozo, M., Navarro, J. A., López-Gambero, A. J., Baixerás, E., Serrano-Castro, P. J., Suárez, J., et al. (2025) · Nutrients · doi:10.3390/nu17183024 · Cited by 1
AI in Clinical Neuroscience Practice
Rudroff, T. (2025) · Neurocultural health and wellbeing · doi:10.1007/978-3-032-11596-6_4 · Cited by 1
Munir, S., Chauhdary, Z., Khan, I. A., Ahmad, M., Khurshid, M., & Ashfaq, U. A. (2026) · Neuropharmacology · doi:10.1016/j.neuropharm.2026.110856 · Cited by 1
Beyond the streetlight: a TREAT‐AD perspective on where to find new Alzheimer's targets
Cary, G. A., Wiley, J. C., Carter, G. W., & Levey, A. I. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71142 · Cited by 1
Efficacy Measures Used in Alzheimer Disease Clinical Trials Between 2015 and 2025
Li, C., Fu, M., Berg, K., Wallach, J. D., Ling, K., Wei, R., Shi, L., Ross, J. S., & Guan, X. (2026) · Neurology · doi:10.1212/wnl.0000000000218373 · Cited by 1
Sharma, V., Vashisht, K., Choudhary, G., Choudhay, V., Bhatia, V., Ashawat, M. S., Baldi, A., & Kushawaha, S. K. (2026) · Inflammopharmacology · doi:10.1007/s10787-026-02392-2 · Cited by 1
Akasaka, H., Yonezawa, H., Takahashi, J., Obara, S., Shibata, T., Suzuki, M., Ishizuka, N., Sato, M., Kudo, M., Terayama, Y., et al. (2020) · Nippon Ronen Igakkai Zasshi Japanese Journal of Geriatrics · doi:10.3143/geriatrics.57.182 · Cited by 1
Yusop, S. N. W., Imran, S., Adenan, M. I., Ashraf, K., & Sultan, S. (2021) · Steroids · doi:10.1016/j.steroids.2021.108832 · Cited by 1
(2022) · Medical & Clinical Research · doi:10.33140/mcr.07.12.07 · Cited by 1
JNK (c-Jun N-Terminal Kinase) Inhibitor IQ-1S Suppresses Premature Aging of OXYS Rat Brain
Александровна, Ж. А., Osipenko, A. N., Tikhonov, D. I., Logvinov, S. V., Плотников, М. Б., Khlebnikov, А. I., & Kolosova, N. G. (2023) · Нейрохимия · doi:10.31857/s1027813323030214 · Cited by 1
Pharmacogenomic approaches to the treatment of sporadic Alzheimer’s disease
Baril, A., Dauar, M. T., Aumont‐Rodrigue, G., Picard, C., & Poirier, J. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-19041-4.00056-x · Cited by 1
Yamaguchi, T., Sasaki, H., Yatsu, G., Koyama, K., & Kinoshita, K. (2024) · Journal of Natural Medicines · doi:10.1007/s11418-024-01862-7 · Cited by 1
Saleh, A. Y., Saputra, D. A. Y., Valentina, R., & Susanto, T. D. (2025) · F1000Research · doi:10.12688/f1000research.160416.2 · Cited by 1
Liu, L., Jiang, M., Zhang, Y., Lv, L., Wang, X., & Yang, X. (2025) · Brain Research · doi:10.1016/j.brainres.2025.149878 · Cited by 1
Demenzerkrankungen: Relevantes für den HNO-Arzt
Dodel, R. C., & Völter, C. (2020) · HNO · doi:10.1007/s00106-020-00814-3 · Cited by 1
An Alternate View of Neuroprotection with Peptides in Alzheimer’s Disease
King, S. P., & Suphioglu, C. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.91065 · Cited by 1
Du, X., Wang, Z., Lv, Z., Ma, L., Ye, S., Liu, F., Zhang, R., Cao, H., & Li, C. (2020) · Biologicals · doi:10.1016/j.biologicals.2020.02.004 · Cited by 2
Demenzfrüherkennung: nur zerstreut oder schon krank?
Dodel, R. C., & Deuschl, G. (2020) · MMW - Fortschritte der Medizin · doi:10.1007/s15006-020-0011-0 · Cited by 1
Gallium nanoparticles as novel inhibitors of Aβ40 aggregation
Torres, K. M., Delgado, A. S., Serrano, E. R., Falcón‐Cruz, N. V., Meléndez, A., Ramos, I., Du, D., & Oyola, R. (2021) · Materials Advances · doi:10.1039/d1ma00461a · Cited by 1
Alzheimer’s Disease: What Do We Know About It and How Can We Tackle It?
Mirpuri, B. (2022) · International journal of high school research · doi:10.36838/v4i2.13
Editorial: Alzheimer’s Disease: Original Mechanisms and Translational Impact
Mancuso, C., & Gaetani, S. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00157 · Cited by 1
Ouk, M. (2020) · TSpace (University of Toronto) · Cited by 1
Yang, J., Ding, W., Zhu, B., Zhen, S. Y., Kuang, S., Zhang, C. M., Wang, P., Yang, F., Yang, L., Yin, W. H., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.06.05.447217 · Cited by 1
Kotredes, K. P., Oblak, A. L., Pandey, R. S., Lin, P. B., Garceau, D. T., Williams, H. M., Uyar, A., O’Rourke, R., O’Rourke, S., Ingraham, C. M., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-580913/v1 · Cited by 1
Asociaciones entre dieta y función cognitiva en el Proyecto SUN
Muñoz, M. I. (2022) · Deposito Adademico Digital Universidad De Navarra (University of Navarra) · doi:10.15581/10171/63292 · Cited by 1
Bongarzone, S., & Gee, A. D. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00474
Hank, N. C., Pereira, J., McCravey, B., Christians, L., Hoggan, C., & Dechoux, F. (2018) · Journal of Clinical Trials · doi:10.4172/2167-0870.1000357
What Are the Appropriate Boundaries of Imagination?
Ellison, J. M., & Kyomen, H. H. (2019) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2019.05.007
The impact of proteostasis imbalance on proteome solubility
Sui, X. (2019) · Minerva Access (University of Melbourne)
Tiwari, S. (2019) · FIU - Digital Commons (Florida International University) · doi:10.25148/etd.fidc007683
Nanolipidic Carriers as Potential Drug Delivery Vehicles in Alzheimer’s Disease
Talegaonkar, S., Gautam, N., Varshney, V., Sharma, S., & Bhattacharyya, A. (2019) · Springer eBooks · doi:10.1007/978-3-030-30930-5_13
Investigating the role of normal and abnormal beta-amyloid processing in cognition
Freeman, T. J. (2019) · ORCA Online Research @Cardiff (Cardiff University)
Worley, S. L. (2019) · PubMed Central
Matiytsiv, N. P., & Chernyk, Y. I. (2020) · Cytology and Genetics · doi:10.3103/s0095452720030081
Alghamdi, S. S. (2020) · doi:10.21007/etd.cghs.2019.0492
Pharmacogenomic approaches to the treatment of sporadic Alzheimer’s disease
Poirier, J., Nilsson, N., Dauar, M. T., Miron, J., & Picard, C. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813955-4.00006-4
Muthuraman, A., Ramesh, M., & Kumar, T. V. R. (2020) · Springer eBooks · doi:10.1007/978-981-15-5167-3_6
Hussain, T., Rizvi, S. M. D., Subaiea, G. M., Alanazi, A. S., & Moin, A. (2020) · Tropical Journal of Pharmaceutical Research · doi:10.4314/tjpr.v19i6.18
Huang, Y. H., Jia, H., & Bao, W. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-816475-4.00013-6
Alzheimer's disease research: past approaches and future directions
Yehuda, M. B., Lawson, J., & Raymont, V. (2021) · British Journal of Neuroscience Nursing · doi:10.12968/bjnn.2021.17.1.34
The Current Advance of Clinical Drug for Treatment Alzheimer’s Disease and the Research of New Drug
Yazhen, S. (2020) · Archives in Neurology & Neuroscience · doi:10.33552/ann.2020.09.000701
Beyond the budget silo approach: estimating health system sustainability for future dementia drugs
Gozzo, L., Benfatto, G., Giorgianni, F., Sultana, J., Rossi, E. A. L., Longo, L., Mansueto, S., Vitale, D. C., Savoca, C., Caraci, F., et al. (2020) · doi:10.36118/pharmadvances.03.2020.01
Caligiuri, M. E. (2021) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.27773
Song, L., Oseid, D. E., Wells, E. A., Coaston, T. N., & Robinson, A. S. (2021) · Research Square · doi:10.21203/rs.3.rs-647000/v1
Lucero, E., Freund, R. K., Johnson, N. R., Dooling, B. R., Sullivan, E. M., Prikhodko, O., Ahmed, M. M., Dell’Acqua, M. L., Chial, H. J., & Potter, H. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.09.09.459627
Drug development and Alzheimer's disease
Delrieu, J., & Vellas, B. J. (2022) · Wiley eBooks · doi:10.1002/9781119484288.ch68
Social and Private Costs of Dementia
Cloos, P., Knapp, M. R. J., Luyten, J., Schokkaert, E., & Shi, C. (2022) · Cambridge University Press eBooks · doi:10.1017/9781108918954.015
Dementia therapeutics and cognitive rehabilitation
Scuteri, D., Bagetta, G., & Nicotera, P. (2022) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2022.102237
Interventions médicamenteuses et non médicamenteuses dans la maladie d’Alzheimer
Paccalin, M. (2022) · Elsevier eBooks · doi:10.1016/b978-2-294-76331-1.00015-x
Impact of aging on the central nervous system: Approaches for antiaging
Yavaş, G., & Mut, M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-98804-9.00023-2
Mechanisms of Thai medicinal plant extracts on the attenuation of glutamate-mediated neurotoxicity
Prasansuklab, A. (2017) · Chula Digiverse · doi:10.58837/chula.the.2017.156
Development of Aβ and anti-Aβ dynamics models for Alzheimer’s disease
Cindyawati, C., Ahmad, F., Hardhienata, H., & Kartono, A. (2024) · Computational and Mathematical Biophysics · doi:10.1515/cmb-2024-0008
The Role of Biophysics in Modern Life Sciences
Ivanitskii, G. R. (2024) · Биофизика · doi:10.31857/s0006302924040237
Orexin Receptor System: Molecular Insights and Therapeutic Implications
Sharma, P., Choudhary, G., Sachdeva, M., Mehta, G., & Tripathi, R. (2024) · Current Drug Therapy · doi:10.2174/0115748855312643241004111641
Ryoo, N., Park, J., Kim, E., Yoon, B., Kim, S., & Shim, Y. (2024) · Journal of Cognitive Intervention and Digital Health · doi:10.58558/jcd.2024.3.1.1
The Role of Biophysics in Modern Life Sciences
Ivanitskii, G. R. (2024) · BIOPHYSICS · doi:10.1134/s000635092470088x
Saleh, A. Y., Saputra, D. A. Y., Valentina, R., & Susanto, T. D. (2025) · F1000Research · doi:10.12688/f1000research.160416.1 · Cited by 1
Liu, W., Zhao, Y., Rao, Y., Wu, Z., Peng, Y. F., & Gong, L. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1514054
Maloney, E. K., Bleakley, A., & White, A. J. (2025) · Research on Aging · doi:10.1177/01640275251346851
The global patent landscape of the drugs for treating Alzheimer’s disease from 2014–2023
Xu, Y., & Gao, Y. Z. (2025) · BMC Neurology · doi:10.1186/s12883-025-04352-9
Park, J.-S., Kam, T.-I., Lee, S., Park, H., Oh, Y., Kwon, S.-H., Song, J.-J., Kim, D., Kim, H., Jhaldiyal, A., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14489894
Swanson, C. J., Zhang, Y., Dhadda, S., Wang, J., Kaplow, J. M., Lai, R. Y. K., Lannfelt, L., Bradley, H., Rabe, M. P., Koyama, A., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14444875
Self-citationXiao, S., Chan, P., Wang, T., Hong, Z., Wang, S., Kuang, W., He, J., Pan, X., Zhou, Y., Ji, Y., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14235007
Self-citationPammolli, F., Righetto, L., Abrignani, S., Pani, L., Pelicci, P. G., & Rabosio, E. (2020) · Figshare · doi:10.6084/m9.figshare.12109518
Machado, A., Ferreira, D., Grothe, M. J., Eyjolfsdottir, H., Almqvist, P. M., Cavallin, L., Lind, G., Linderoth, B., Seiger, Å., Teipel, S., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12262178
McDade, E., Cummings, J. L., Dhadda, S., Swanson, C. J., Reyderman, L., Kanekiyo, M., Koyama, A., Irizarry, M. C., Kramer, L. D., & Bateman, R. J. (2023) · Figshare · doi:10.6084/m9.figshare.22603849
Self-citationZhou, Y., Fang, J., Bekris, L. M., Kim, Y. H., Pieper, A. A., Leverenz, J. B., Cummings, J. L., & Cheng, F. (2021) · Figshare · doi:10.6084/m9.figshare.13572118
Self-citationAssessment of Healthcare Resource Requirements for Disease-Modifying Dementia Therapies in Türkiye
Avşar, T. S. (2025) · Sağlık Bilimleri Dergisi · doi:10.34108/eujhs.1675326
Ham, H. J., Park, S. S., Lee, Y. S., Kim, T. H., Son, D. J., Kim, J.-H., Lim, K., Park, H., Lee, H. J., Yun, J., et al. (2026) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2025.1728279
Penny, L. K., Arastoo, M., Lofthouse, R. A., Abdallah, A., Imoesi, P. I., Schwab, K., Shiells, H., Melis, V., Riedel, G., Harrington, C. R., et al. (2026) · Alzheimer s Research & Therapy · doi:10.1186/s13195-026-01985-x
Lee, A. L. Y., Wei, A. C., & Yeong, K. Y. (2026) · Drug Discovery Today · doi:10.1016/j.drudis.2026.104651
Ding, Z. (2025) · International Conference on Power, Electrical Engineering, Electronics and Control (PEEEC) · doi:10.1109/peeec67807.2025.00029
NMR study of 14-3-3 protein-protein interactions and modulation thereof by small molecules
Neves, J. F. (2019) · theses.fr (ABES) · doi:10.70675/6952dbaezebb9z4212z9c01z6ea8f2190a06
Toublet, F. (2019) · theses.fr (ABES) · doi:10.70675/ce2e69d8zf6fez40cdz9605z8b0883cefb6a
Cosenz, F., & Domenico, F. D. (2026) · European Journal of Innovation Management · doi:10.1108/ejim-10-2025-1382 · Cited by 1
La place des biomarqueurs dans les essais de prévention de la maladie d'Alzheimer
Delrieu, J. (2021) · theses.fr (ABES) · doi:10.70675/2b5f4719z01f9z4376z9dabzd5a185dc4d79
Martínez-Orozco, H., Andrade-Guerrero, J., Pasten-Castrejón, N. J., Rodríguez‐Tanty, C., & Díaz-Cintra, S. Y. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71589
Small Molecules as Anti-Alzheimer’s Scaffolds
Hazra, R., Roy, S., Gayen, S., Parui, A., Arshad, A., Roy, N., & Sarkar, A. N. (2026) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898815646126010013
Maloney, E. K., Bleakley, A., Hull, S. J., & Langbaum, J. B. S. (2026) · Health Communication · doi:10.1080/10410236.2026.2706529
El‐Fakharany, E. M., Ali, F. K., El-Sayed, M. H., Alfaifi, M. Y., Shati, A. A., Elbehairi, S. E. I., Atwa, A., Alian, A., Gadelmawla, M. H. A., El-Sharouny, E. E., et al. (2026) · Chemical Papers · doi:10.1007/s11696-026-05374-4
Bilginer-Kartal, R., & Yıldız, A. A. (2026) · Biophysica · doi:10.3390/biophysica6050086
Energy and Information in Living Systems. Biophysical Analysis
Ivanitskii, G. R., & Maevskiĭ, E. I. (2026) · BIOPHYSICS · doi:10.1134/s000635092670034x
Devi, D., Rani, A., Singh, J., Quasmi, M. N., Jangra, A., & Kumar, D. (2026) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-026-02731-y
Therapeutic intervention strategies in frontotemporal dementia: drug development pipeline
Perrone, F., Locuratolo, N., Carbone, E., Cappella, M., Rivabene, R., Fabrizi, E., Talarico, G., Vanacore, N., Lacorte, E., & Piscopo, P. (2026) · Alzheimer's & Dementia · doi:10.1002/trc2.70243
The correlation between Alzheimer’s disease clinical features and MRI observations
To’xtasinova, M. (2026) · Eurasian Journal of Medical and Natural Sciences · doi:10.70413/ejmns-v06-i04-s39286
BindingDB (2022) · UC San Diego · doi:10.7270/q2708571
BindingDB (2021) · UC San Diego · doi:10.7270/q2bp068p
Metadata
- Authors
- Cummings, J., Lee, G., Ritter, A., & Zhong, K.
- Affiliations
- Cleveland Clinic (US)
- Global Alzheimer's Platform Foundation (US)
- Corresponding author
- Cummings, Jeffrey
- Venue
- Alzheimer's & Dementia: Translational Research & Clinical Interventions
- Publisher
- Wiley
- Published
- 2018-01
- Volume
- 4
- Issue
- 1
- Pages
- 195-214
- ISSN
- 2352-8737 (ISSN-L)
- PMC
- PMC6021548
- OpenAlex
- W2918066696
- Cited by
- 697
- References
- 48
- Citations by year
- 2026: 19 · 2025: 28 · 2024: 39 · 2023: 22 · 2022: 55 · 2021: 138 · 2020: 177 · 2019: 170 · 2018: 42
- FWCI
- 91.11
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Alzheimer s & Dementia Translational Research & Clinical Interventions (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- National Institute of General Medical Sciences (P20GM109025)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, drug development pipeline, clinical trials, disease-modifying therapy, amyloid biomarkers, prodromal Alzheimer's disease, preclinical Alzheimer's disease, neuropsychiatric symptoms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
